Compare Abeona Therapeutics Inc (ABEO) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs HCA Health Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while HCA Health Inc trades at $411.81 (market cap $89.08B). The key difference: HCA Health Inc is far larger — about 211.5× Abeona Therapeutics Inc's market cap, and HCA Health Inc pays a 0.76% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HCA | |
|---|---|---|
Market Cap | $421.19M | $89.08B |
Sector | Health | Health |
52-Week High | $7.45 | $545.13 |
52-Week Low | $4.17 | $361.32 |
Enterprise Value | $276.10M | $139.62B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
HCA Healthcare trades at $414.66, up 0.15% today, with a bullish technical signal from moving averages and a P/E of 13.8. Revenue grew to $75.60B in 2025, with net income of $6.78B, and the company has beaten EPS estimates for three consecutive quarters. Recent corporate actions include a $0.78 dividend scheduled for September 2026.
The outlook is positive with a consensus price target of $449.93, implying 8.5% upside, supported by strong earnings and institutional buy ratings. Risks include high debt levels, regulatory investigations, and expense pressures noted in Q2 2026 results. Investors should weigh solid fundamentals against legal and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
